肺癌の免疫治療における腫瘍免疫機能とPET/MRIを用いた画像情報の統合解析

点击翻译按钮获取中文摘要

【Methods】We evaluated the peripheral blood neutrophil-lymphocyte ratio and each blood cell component, and FLT accumulation in secondary lymphoid tissues such as spleen and hematopoietic tissues such as bone marrow, before and after ICI treatment , to determine their relationship to the therapeutic effect of ICI.【Results】The median age was 70.4 years, 23 (92%) were male. The histologic types were adenocarcinoma, squamous cell carcinoma, and others in nine (36%), 11 (44%), and four (16%) patients, respectively. Confirmed responses were CR, PR, SD, and PD in one (4%), seven (28%), eight (32%), and nine (36%) patients, respectively.The median changes of SUVs between baseline and two and six weeks after PD-1 inhibitor treatment for the spleen (ΔSUVmean0-2 and ΔSUVmean0-6) was 5.44% and -4.72%, respectively. These values did not differ significantly between the non-PD and PD groups (ΔSUVmean0-2 7.57 vs. -3.61, P = 0.60; ΔSUVmean0-6 -5.28 vs. 3.44, P = 0.69). The changes in any 18F-FLT PET parameters (ΔSUVmax0-2, ΔSUVmean0-2, ΔPPV/BSA0-2, and ΔTVP/BSA0-2) of any thoracic vertebrae (Th4, 8, and 12) between baseline and two weeks later were not significantly different between the non-PD and PD groups, although the 18F-FLT accumulation tended to decrease in the non-PD group and increase in the PD group two weeks after treatment initiation. All parameters of change of 18F-FLT accumulation in the thoracic vertebrae between baseline and 6 weeks after treatment initiation, except ΔSUVmean0-6 in Th4, were significantly lower in the non-PD group than in the PD group.